博暉創新(300318.SZ)2020年度預盈580萬-850萬元
格隆匯 1 月 29日丨博暉創新(300318.SZ)公佈,預計2020年度歸屬於上市公司股東的淨利潤580萬元-850萬元,上年同期盈利254.28萬元;扣除非經常性損益後的淨利潤290萬元-560萬元。
報吿期公司歸屬於上市公司股東的淨利潤較上年同期增長,主要原因為:1、受新冠疫情影響,公司檢驗檢測業務收入同比有所下降,但通過成本費用控制,利潤同比改善;2、血液製品業務持續拓展,營業收入同比增長,利潤有所改善。3、預計非經常性損益對歸屬於上市公司股東的淨利潤影響金額約為290萬元,上年同期為1386.69萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.